Consistently, double immunofluorescence showed that compared to controls, rats treated with vx-765 showed inhibited secretion of GSDMD in astrocytes in the peri-infarct region after MCAO, 3 days after stroke (Figure 7D), validated by findings of a transmission electron microscope (Figure 7E), in which membrane pores were less frequent in vx-765-treated, compared to vehicle-treated, MCAO rats. This evidence concerns the gene GSDMD and stroke disorder.